Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2011. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 575,000 Ordinary shares of 25 pence each.
- Purchase Price Range: High of 1,179.0 pence; Low of 1,162.5 pence per share.
- Treasury Shares Held: 483,179,284 shares (8.52% of total issued share capital).
- Treasury Shares (Including Unsettled): 484,609,284 shares (9.34% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,187,679,249 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 575,000 shares on February 24, 2011. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. The document serves strictly as a notification of a completed share buyback and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (483,179,284 settled vs. 484,609,284 including unsettled).
- Confirm the percentage of total voting rights represented by Treasury shares (9.34%).
- Check the denominator for Disclosure and Transparency Rules calculations (5,187,679,249 shares in issue).
- Review the price range paid for the specific tranche of 575,000 shares (1,162.5 to 1,179.0 pence).